title: Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.forename: Fangxin
authors.initials: F
authors.lastname: Hong
authors.forename: Sandra J
authors.initials: SJ
authors.lastname: Horning
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
authors.forename: Judith
authors.initials: J
authors.lastname: Manola
authors.forename: Lode J
authors.initials: LJ
authors.lastname: Swinnen
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Habermann
authors.forename: Kristen
authors.initials: K
authors.lastname: Ganjoo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone